Regenerative Medicines Consortium Project
AusBiotech is leading a consortium of seven partners as the Australian regenerative medicine (RM) industry prepares to thrive and drive benefits to Australia’s economy and the health of its people, after it received funding through MTPConnect’s Project Fund Program.
This 12-month project will identify and establish a national RM sector ‘catalyst’ collaboration body, and address priority action areas including: workforce capabilities, collaboration, funding, regulation and policy infrastructure, and Australian manufacturing capability.
The seven consortium partners hold extensive insight and experience in the life science and regenerative medicines landscape in Australia: AusBiotech, Medicines Australia, Cell Therapies Pty Ltd, Novartis Pharmaceuticals Australia Pty Ltd, Biointelect Pty Ltd, Research Strategies Australia, and MTPConnect. The partners will match the funding from MTPConnect to deliver the project.
Read more about the project, its major deliverables, and the significance of regenerative medicine’s potential here.
To support Australian patients accessing world-class RM therapies that are sustained by a thriving Australian RM industry, a strategic roadmap for the Australian RM sector has been released. The first strategy of its kind, it seeks to create an end-to-end world-class value chain that can discover, develop, and distribute RM, while creating jobs, commercialising research, exporting Australian therapies to the world, and attracting global therapies for Australian patients. The roadmap articulates the objectives and priority actions, backed by a detailed discussion of the key barriers facing the RM sector. The five key strategic goals include: capabilities/workforce; collaboration; funding; regulation and policy; and infrastructure. Read more about the Strategic Roadmap for the Regenerative Medicine Sector here, and download the full Strategic Roadmap here. |
Investment in Australian RM companies grew with a 113 per cent increase in private funding over the period between 2019 and 2020, reveals the newly-published Australia’s Regenerative Medicine Investments Database report. With $394.1 million invested into RM in 2020, this accounts for approximately 23 per cent of the overall capital invested into the Australian biotech sector in 2020. Read more about the Database here, or download the full document here. |
Four case studies demonstrating a depth of information on cell and gene technology development and their potential for addressing and managing unmet needs, has been released. RM is a multidisciplinary field that seeks to develop the science and tools that can help repair, augment, replace, or regenerate damaged or diseased human cells, tissues, genes, organs, or metabolic processes, to restore normal function. It is a complex field addressing complex conditions, and the case studies are an important tool for increasing understanding of the science and the opportunities available. The four case studies each focus on a different aspect of cell and gene technology: Cell therapy (Mesoblast), Gene therapy (Pfizer), Gene Modified Cell (Novartis) and Tissue Engineered Products (Orthocell). Read more about the Case studies here or download the full document here. |
The globe is anticipating an avalanche of new and novel regenerative medicine (RM) treatments, reveals Australia’s Regenerative Medicine Global Pipeline Tracker, and Australia may share in access to some. This inaugural report horizon-scanned the global pipeline of products in this emerging field of medicine, and postulates which might come to Australia for patient access. While there are currently six RM therapies already approved in Australia , the new data shows a rich pipeline with 140 therapies in late-stage development globally in multiple therapeutic areas, and up to nine may reach Australian patients in the next five years Read more about the report here, or download the full report here. |
This report provides a recommendation for a funding and model structure for the Regenerative Medicine (RM) sector ‘catalyst’ collaboration body, with a scope that includes industry as a key component within a broader sector. This report includes both the recommendation for the funding and model structure and the detailed analysis used to determine the sustainable funding and model structure for a RM sector ‘catalyst’ collaboration body. The analysis includes detailed research into models that are used for similar purposes in other sectors. Download the full report here, or contact AusBiotech if you're interested in learning more about or contributing to the new Catalyst. |
 NEW: Australia’s Regenerative Medicine Manufacturing Capacity & Capability This report provides a new evidence base and model against which to map, build and strengthen our sovereign GMP manufacturing position over time. By leveraging Australia’s reputation for delivering high-quality, complex, and safe medical products, as well as our highly-skilled workforce, we can become the clinical trials and manufacturing hub for the region and deliver potentially life-changing treatments to patients, both in Australia, and the broader Asia Pacific region. RM therapies require highly-specialised GMP capabilities and infrastructure, a highly-skilled workforce, and complex supply chains. The increasing demand for RM therapy manufacturers is growing and a major bottleneck exists at the GMP manufacturing phase of product development, both in Australia and globally. This progressive direction demonstrates that Australia’s capabilities are growing and greater opportunities are available for the sector if further investment is pledged. Investing in and building Australia’s sovereign manufacturing capability for complex and advanced RM therapies will ensure faster access to cutting-edge treatments for Australian patients, create new jobs now and for the future, and develop a highly skilled workforce. Read more about the report here, or download the full report here.
|
Australia is an active, globally-popular, and internationally-competitive destination for clinical trials with a bountiful pipeline of RM therapies seeking to join the six regenerative medicines already approved in Australia. Delivering clarity of the development landscape, the inaugural CT Database captures the portion of clinical trials in RM, and seeks to categorise them into type and phase. This benchmarking is important as the sector prepares to thrive, and enables the ecosystem to develop in a way that capitalises on the opportunities that present now and in the future. Read more about the report here, or download the full report here. |
 NEW: The Regenerative Medicine Value Chain, The pathway from discovery to patient delivery With new thinking and approaches necessitated by emerging, transformative and disruptive regenerative medicine (RM) therapies, this report considers how to best strengthen the pathway from discovery to patient delivery. The comprehensive Regenerative Medicine Value Chain report considers the chain of activities involved in RM therapy development, including: research capabilities - workforce and infrastructure; supporting Australian research and small and medium-sized enterprises: funding, investment and partnerships; attracting investment in clinical trials; streamlined approvals and incentives; clear pathways to patient delivery: healthcare system preparedness; and data-driven approaches across the value chain. Read more about the report here, or download the full report here. |
NEW: Strategic Roadmap for the Regenerative Medicine Sector
AusBiotech is delighted to be joining with a high-quality consortium of organisations to further build the foundations for regenerative medicine in Australia.
The potential health benefits of a surging regenerative medicine sector, were until quite recently more likely to be considered science fiction than reality, but the evidence is mounting; the outcome's stunning; and the excitement for the sector's future is too good to ignore.
However, Australia is underprepared to capitalise on the opportunities gene and cell therapies can deliver. This project will bring together, for the first time, the entire ecosystem, and focus our efforts for best effect. From SME to multinational, investor to manufacturer, patient to employee, this project will prepare us for the road ahead.
- AusBiotech CEO , Lorraine Chiroiu
The consortium project will receive $300,000 funding through MTPConnect’s Growth Centre Project Fund Program, an Australian Government initiative supported by the Department of Industry, Science, Energy and Resources. Consortia members are providing $300,000 in matched funding. It is a competitive matched funding program that aims to invest in ideas to boost the innovation, productivity and competitiveness of Australia’s MTP sector.